Ester Sánchez-Tilló
Research group
- Gastrointestinal and pancreatic oncology Accredited researcher (R3A)
About me
Accredited researcher (R3A), formerly Miquel Servet. I have a PhD in biochemistry and I3 certification. We are currently investigating the role of ubiquitin ligases in oncogene-driven colorectal cancer development, metastasis and response to treatment.Our goals are to elucidate novel mechanisms, to identify diagnostic and prognostic markers for the different subtypes, and to identify novel therapeutic targets.We use molecular and cellular techniques in patient samples and preclinical models such as organoids and in vivo models. With more than 4,000 citations, this work has resulted in relevant publications in the fields of gastroenterology, cell and molecular biology and oncology.
Featured publications
-
The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas
Authors:Reference: Jci Insight 2023. -
ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1
Authors:Reference: Gut 2017. -
ZEB1 and TCF4 reciprocally modulate their transcriptional activities to regulate Wnt target gene expression
Authors:Reference: Oncogene 2015. -
The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma
Authors:Reference: Cell Death And Differentiation 2014. -
Rb1 family mutation is sufficient for sarcoma initiation
Authors:Reference: Nature Communications 2013. -
Sequential Inductions of the ZEB1 Transcription Factor Caused by Mutation of Rb and Then Ras Proteins Are Required for Tumor Initiation and Progression
Authors:Reference: Journal Of Biological Chemistry 2013. -
ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1
Authors:Reference: Clinical Cancer Research 2013. -
EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness
Authors:Reference: Cellular And Molecular Life Sciences 2012. -
β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness.
Authors:Reference: Proceedings Of The National Academy Of Sciences Of The United States Of America 2011.
Featured Projects
-
Plataforma ISCIII de Biomodelos y Biobancos. Fortalecimiento del Biobanco, acreditado con la nueva norma ISO 20387:2020 de biobancos, para la optimización del catálogo de muestras y datos asociados, y ampliación de biomodelos en organoides para la transferencia a la biomedicina
Funder: ISCIII (Programa financiador competitivo)Code: PT23/00124Duration: 01/01/2024 -
GRAIL/RNF128 E3 ligase in colon cancer subtypes with KRAS, BRAF, and APC mutations
Principal investigator: Ester Sánchez TillóFunder: ISCIII (Instituto de Salud Carlos III)-Subdireccion General de EvaluacionCode: PI18/00244Duration: 01/01/2019 - 31/12/2021 -
ZEB1 role in oncogenic transformation and tumorigenesis of CRC by Wnt, KRas and Braf pathways
Principal investigator: Ester Sánchez TillóFunder: CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (Sede o evento); Universidad Complutense de MadridCode: CP13/00200Duration: 31/01/2014 - 31/01/2017 -
Characterization of ZEB1/microRNA pathway as a prognostic biomarker of metastatic ability of colorectal carcinomas and their chemoterapeutic response. Validation of ZEB1 as a potential therapeutic target
Funder: CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (Sede o evento); Acadèmia de Ciències Mèdiques de Catalunya i de BalearsDuration: 01/04/2013 - 31/05/2015 -
Identification of gene expression profiles regulated by the microRNA/ZEB1-ZEB2 pathway and its role in the invasive and metastatic behavior of breast tumors and their response to treatment.
Funder: CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (Sede o evento)Duration: 01/09/2012 - 31/12/2013